GLP-3 RT
Price range: $79.99 through $160.00
| Quantity | Price | Discount |
|---|---|---|
| 5-10 | $76.79 | 4% |
| 11-15 | $73.59 | 8% |
| 16-20 | $70.39 | 12% |
| 21+ | $67.19 | 16% |
- These products are intended for laboratory research purposes only, and are not for human or animal consumption. The products are not intended to diagnose, treat, cure, or prevent any disease. The products should not be used as a food, drug, cosmetic, or other household use.
Description
GLP-3 RT is a 39-amino acid triple hormone receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. Currently in Phase III clinical development, it has demonstrated the highest weight reduction of any pharmacological compound on record — approximately 28.7% at 68 weeks — through its tri-receptor mechanism that adds hepatic fat oxidation and energy expenditure to dual-agonist effects.
Research Overview
GLP-3 RT engages three incretin and metabolic hormone receptor systems simultaneously, producing additive metabolic effects that exceed single or dual-agonist compounds in comparative studies. The GLP-1 axis drives satiety signaling and slows nutrient absorption; the GIP axis enhances pancreatic insulin response and modulates fat tissue remodeling; the glucagon axis increases hepatic fat oxidation and elevates basal energy expenditure.
Phase II data reported a mean body weight reduction of ~24.2% over 48 weeks. Phase III TRIUMPH-4 trial data extended this to ~28.7% (71.2 lbs) at 68 weeks with a 12mg dose. Phase III development is ongoing; regulatory review is anticipated 2026–2027.
Key Features
- 39-amino acid synthetic peptide; trade designation LY3437943
- Triple agonist: GLP-1 (appetite suppression), GIP (insulin sensitivity), glucagon (energy expenditure)
- Long half-life: ~6 days; peak plasma concentration at ~1 day
- Once-weekly subcutaneous dosing in clinical trials
- Phase III TRIUMPH-4 data: ~28.7% mean weight loss at 68 weeks (12mg dose)
- Superior efficacy vs. dual-agonist (GLP-2) and single-agonist mechanisms in trial comparisons
Common Research Uses
- Commonly studied for weight reduction and adiposity regulation via triple receptor activation
- Researched in relation to glycemic control, insulin sensitivity, and GLP-1/GIP axis co-activation
- Investigated for hepatic fat reduction through glucagon receptor engagement
- Studied in models of cardiovascular metabolic risk and metabolic syndrome
- Researched for comparative efficacy vs. dual-agonist (tirzepatide) mechanisms
Product Specifications
- Format: Lyophilized powder
- Vial size: 10mg
- Storage: Freeze at −20°C (lyophilized); refrigerate at 2–8°C after reconstitution; use within 28 days
Disclaimer: For research purposes only. Not for human consumption.
| Net Content | 10mg, 20mg, 30mg |
|---|
RELATED PRODUCTS
GHK-CU
Price range: $30.00 through $44.00
